Sugi Predict

Sugi Predict / Targets / MAP2K2

MAP2K2

Dual specificity mitogen-activated protein kinase kinase 2 · P36507 · MAP2K2 on Sugi Atlas →

74,996 patent compounds predicted against MAP2K2, 55,032 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL189265 SCHEMBL189265 0.80 20/20
SCHEMBL189491 SCHEMBL189491 0.78 20/20
SCHEMBL189374 SCHEMBL189374 0.75 20/20
SCHEMBL188543 SCHEMBL188543 0.67 20/20
SCHEMBL187560 SCHEMBL187560 1.00 19/20
SCHEMBL188324 SCHEMBL188324 1.00 19/20
SCHEMBL188571 SCHEMBL188571 1.00 19/20
Cobimetinib Cobimetinib (SCHEMBL188704) 1.00 19/20
SCHEMBL188883 SCHEMBL188883 1.00 19/20
SCHEMBL188890 SCHEMBL188890 1.00 19/20
SCHEMBL189116 SCHEMBL189116 1.00 19/20
Cobimetinib Cobimetinib (SCHEMBL189565) 1.00 19/20
SCHEMBL189480 SCHEMBL189480 0.95 19/20
SCHEMBL188803 SCHEMBL188803 0.83 19/20
SCHEMBL188734 SCHEMBL188734 0.83 19/20
SCHEMBL189091 SCHEMBL189091 0.80 19/20
SCHEMBL188810 SCHEMBL188810 0.79 19/20
SCHEMBL189027 SCHEMBL189027 0.78 19/20
SCHEMBL188737 SCHEMBL188737 0.77 19/20
SCHEMBL189472 SCHEMBL189472 0.77 19/20

Clinical trials — most relevant to MAP2K2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas PHASE2ACTIVE_NOT_RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma PHASE2ACTIVE_NOT_RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma PHASE2COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults PHASE1NOT_YET_RECRUITING
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer nanNOT_YET_RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation nanCOMPLETED
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 nanCOMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP2K2 binder may also engage these)

ProteinNameSimilarity
Q90321 — 1.000 Q90321 →
Q90891 — 1.000 Q90891 →
Q1HG70 — 1.000 Q1HG70 →
P36506 — 1.000 P36506 →
P31938 — 1.000 P31938 →
Q91447 — 1.000 Q91447 →
Q63980 — 1.000 Q63980 →
Q05116 — 1.000 Q05116 →
Q9XT09 — 1.000 Q9XT09 →
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 0.999 landscape →
P29678 — 0.998 P29678 →
Q24324 — 0.997 Q24324 →
Q01986 — 0.997 Q01986 →
Q4KSH7 — 0.995 Q4KSH7 →
Q63932 — 0.995 Q63932 →
MAP2K7 Dual specificity mitogen-activated protein kinase kinase 7 0.995 landscape →
Q10664 — 0.992 Q10664 →
Q99078 — 0.990 Q99078 →
P47809 — 0.990 P47809 →
MAP2K4 Dual specificity mitogen-activated protein kinase kinase 4 0.989 landscape →
Q9Y884 — 0.989 Q9Y884 →
Q20347 — 0.989 Q20347 →
Q5QN75 — 0.989 Q5QN75 →
Q07192 — 0.988 Q07192 →
Q9DGE0 — 0.987 Q9DGE0 →
Q9NB31 — 0.987 Q9NB31 →
A4K2M3 — 0.987 A4K2M3 →
Q9WVS7 — 0.986 Q9WVS7 →
Q5E9L6 — 0.986 Q5E9L6 →
A4K2Y1 — 0.986 A4K2Y1 →